Trial Information

Summary: A Prospective, Multicenter, Open-Label, Comparative, Efficacy Study of Pegasys plus Copegus in Treatment-Naive Latino Patients with Chronic Hepatitis C-Genotype 1, as Compared to Treatment-Naive Non-Latino Caucasian Patients with Chronic Hepatitis C-Genotype 1 (ML18179)

This study is for Latino or Non-Latino Caucasian patients who have Chronic Hepatitis C infection that has never been treated with interferons or ribavirin. Study participants will receive the medications Pegasys and Copegus at the same time.
All study medications and procedures will be provided for free. Patients will be reimbursed for travel expenses ($25 per visit). There will be about 17 clinic visits over 1 1/2 years.
Compensation Provided

Patient Inclusion/Exclusion Criteria:

You may be able to participate if you
-are male or female 18-65 years old
-have been diagnosed with Chronic Hepatitis C
-agree to not drink any alcohol during study participation
-meet additional entry criteria

You will not able to participate if you
-have had previous therapy with interferon or ribavirin
-are pregnant or breastfeeding
-are HIV positive
-have a history of depression
-have a history of cancer

If you would like to learn more about participating in this study, please send an e-mail message using the form below.